No differences between drug naive and drug experienced unipolar depressed patients in terms of neurobiological testing: A cross sectional study

Journal of Psychiatric Research

Volumn 47, Issue 12, 2013, Pages 1984-1990

  Fountoulakis, Konstantinos N ^a   Gonda, Xenia ^b   Andreoulakis, Elias ^a   Fokas, Konstantinos ^a   Iacovides, Apostolos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Antidepressants; Depression; Medicated; Na ve; Neurobiological; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT; DEXFENFLURAMINE; HYDROCORTISONE; PROLACTIN;

ADULT; ARTICLE; ATYPICAL DEPRESSION; BRAIN BLOOD FLOW; BRAIN FUNCTION; BRAIN STEM; CAUDATE NUCLEUS; CEREBELLUM; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEXAMETHASONE SUPPRESSION TEST; DISEASE SEVERITY; ELECTROOCULOGRAM; ELECTRORETINOGRAM; EVOKED VISUAL RESPONSE; FEMALE; FRONTAL LOBE; GLOBUS PALLIDUS; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; INVOLUTIONAL DEPRESSION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL PATIENT; NEUROBIOLOGY; OCCIPITAL LOBE; ONSET AGE; PARIETAL LOBE; PATHOPHYSIOLOGY; PERSONALITY DISORDER; PRIORITY JOURNAL; PROVOCATION TEST; PSYCHOPHARMACOTHERAPY; RELAPSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TEMPORAL LOBE; THALAMUS;

ANTIDEPRESSANTS; DEPRESSION; MEDICATED; NAÏVE; NEUROBIOLOGICAL; TREATMENT;

ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; BRAIN; COGNITION; CROSS-SECTIONAL STUDIES; DEPRESSION; DEXAMETHASONE; ELECTROOCULOGRAPHY; EVOKED POTENTIALS, VISUAL; FEMALE; FUNCTIONAL LATERALITY; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84886093355     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.09.004     Document Type: Article

References (65)

1. APA Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Press, DSM-IV. Washington DC. 4th ed.
2. Arden G., Kelsey J. Changes produced by light in the standing potential of the human eye. JPhysiol 1962, 189-202.
3. Arden G., Barrada A., Kelsey J. New clinical test of retinal function based upon the standing potential of the eye. Br J Ophthalmol 1962, 449-467.
4. Bech P. Rating scales for psychopathology, health status and quality of life 1993, Springer Verlag, Berlin Heidelberg.
5. Bonne O., Krausz Y., Aharon Y., Gelfin Y., Chisin R., Lerer B. Clinical doses of fluoxetine and cerebral blood flow in healthy volunteers. Psychopharmacol 1999, 143:24-28.
6. Brockmann H., Zobel A., Joe A., Biermann K., Scheef L., Schuhmacher A., et al. The value of HMPAO SPECT in predicting treatment response to citalopram in patients with major depression. Psychiatry Res 2009, 173:107-112.
7. Carroll B., Martin F., Davies B. Resistance of suppression by dexamethasone of plasma 11-OHCS levels in severe depressive illness. Br Med J 1968, 3:285-287.
8. Chiappa K. Evoked potentials in clinical medicine 1990, Raven Press, New York.
9. Cole J., Costafreda S.G., McGuffin P., Fu C.H. Hippocampal atrophy in first episode depression: a meta-analysis of magnetic resonance imaging studies. JAffect Disord 2011, 134:483-487.
10. Cowen P.J. Not fade away: the HPA axis and depression. Psychol Med 2010, 40:1-4.
11. Delaveau P., Jabourian M., Lemogne C., Guionnet S., Bergouignan L., Fossati P. Brain effects of antidepressants in major depression: a meta-analysis of emotional processing studies. JAffect Disord 2011, 130:66-74.
12. Di Renzo G., Amoroso S. Pharmacological characterization of serotonin receptors involved in the control of prolactin secretion. Eur J Pharmacol 1989, 162:371-373.
13. Evans D., Golden R. The dexamethasone suppression test: a review. Handbook of clinical psychoneuroendocrinology 1987, 313-335. John Wiley and Sons, New York. C. Nemeroff, P. Loosen (Eds.).
14. Fessler R., Deyo S., Meltzer H., Miller R. Evidence that the medial and dorsal raphe nuclei mediate serotonergically-induced increases in prolactin release from the pituitary. Brain Res 1984, 299:231-237.
15. Fitzgerald P.B., Laird A.R., Maller J., Daskalakis Z.J. Ameta-analytic study of changes in brain activation in depression. Hum Brain Mapp 2008, 29:683-695.
16. Fotiou F., Fountoulakis K.N., Iacovides A., Kaprinis G. Pattern-reversed visual evoked potentials in subtypes of major depression. Psychiatry Res 2003, 118:259-271.
17. Fountoulakis K., Iacovides A., Fotiou F., Karamouzis M., Demetriadou A., Kaprinis G. Relationship among Dexamethasone Suppression Test, personality disorders and stressful life events in clinical subtypes of major depression: an exploratory study. Ann Gen Hos Psychiatry 2004, 3:15.
18. Fountoulakis K.N., Moller H.J. Antidepressant drugs and the response in the placebo group: the real problem lies in our understanding of the issue. JPsychopharmacol 2012, 26:744-750.
19. Fountoulakis K.N., Kontis D. Mathematical coupling and the true role of baseline severity in acute mania trials. Neuropsychopharmacol 2012, 37:850.
20. Fountoulakis K.N., Fotiou F., Iacovides A., Kaprinis G. Is there a dysfunction in the visual system of depressed patients?. Ann Gen Psychiatry 2005, 4:7.
21. Fountoulakis K.N., Iacovides A., Grammaticos P., St Kaprinis G., Bech P. Thyroid function in clinical subtypes of major depression: an exploratory study. BMC Psychiatry 2004, 4:6.
22. Fountoulakis K.N., Kaprinis S.G., Iacovides A., Phokas K., Kaprinis G. Are dexamethasone suppression test nonsuppression and thyroid dysfunction related to a family history of dementia in patients with major depression? An exploratory study. Can J Psychiatry Revue Canadienne de Psychiatrie 2005, 50:342-345.
23. Fountoulakis K.N., Iacovides A., Karamouzis M., Kaprinis G.S., Ierodiakonou C. Season of birth, clinical manifestations and Dexamethasone Suppression Test in unipolar major depression. Ann Gen Psychiatry 2007, 6:20.
24. Fountoulakis K.N., Gonda X., Rihmer Z., Fokas C., Iacovides A. Revisiting the Dexamethasone Suppression Test in unipolar major depression: an exploratory study. Ann Gen Psychiatry 2008, 7:22.
25. Fountoulakis K.N., Iacovides A., Karamouzis M., Gerasimou G., Grammatikos P., Fotiou F., et al. Is it possible to predict the long-term response to venlafaxine with the use of biological markers and psychophysiological methods?. JAffect Disord 2007, 99:155-163.
26. Fountoulakis K.N., Karamouzis M., Iacovides A., Nimatoudis J., Diakogiannis J., Kaprinis G., et al. Morning and evening plasma melatonin and dexamethasone suppression test in patients with nonseasonal major depressive disorder from northern Greece (latitude 40-41.5degrees). Neuropsychobiol 2001, 44:113-117.
27. Fountoulakis K.N., Iacovides A., Gerasimou G., Fotiou F., Ioannidou C., Bascialla F., et al. The relationship of regional cerebral blood flow with subtypes of major depression. Prog Neuro-Psychopharmacol Biol Psychiatry 2004, 28:537-546.
28. Fountoulakis K.N., Iacovides A., Fotiou F., Nimatoudis J., Bascialla F., Ioannidou C., et al. Neurobiological and psychological correlates of suicidal attempts and thoughts of death in patients with major depression. Neuropsychobiol 2004, 49:42-52.
29. Frodl T., Meisenzahl E.M., Zetzsche T., Born C., Jager M., Groll C., et al. Larger amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects. Biol Psychiatry 2003, 53:338-344.
30. Garattini S., Mennini T., Samanin R. From fenfluramine racemate to d-fenfluramine: specificity and potency of the effects on the serotoninergic system and food intake. Ann N Y Acad Sci 1987, 499:156-166.
31. Garattini S., Mennini T., Samanin R. Reduction of food intake by manipulation of central serotonin. Br J Psychiatry 1989, 155:41-51.
32. Geday J., Hermansen F., Rosenberg R., Smith D.F. Serotonin modulation of cerebral blood flow measured with positron emission tomography (PET) in humans. Synapse 2005, 55:224-229.
33. Goldapple K., Segal Z., Garson C., Lau M., Bieling P., Kennedy S., et al. Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry 2004, 61:34-41.
34. Hamilton M. The assessment of Anxiety states by rating. Brit J Med Psychol 1959, 32:50-55.
35. Hamilton M.A. Rating scale for depression. JNeurol, Neurosurg Psychiatry 1960, 23:56-62.
36. Hartshome M. Single photon emission computed tomography. Functional brain imaging 1995, 213-238. Mosby-Year Book Inc, St.Louis. W. Orrison, J. Lewine, J. Sanders, M. Hartshorne (Eds.).
37. Hasler G., Drevets W.C., Manji H.K., Charney D.S. Discovering endophenotypes for major depression. Neuropsychopharmacol 2004, 29:1765-1781.
38. Hunter A.M., Cook I.A., Leuchter A.F. Does prior antidepressant treatment of major depression impact brain function during current treatment?. Eur Neuropsychopharmacol 2012, 22:711-720.
39. Iacovides A., Fountoulakis K.N., Fotiou F., Fokas K., Nimatoudis I., Kaprinis G. Relation of personality disorders to subtypes of major depression according both to DSM-IV and ICD-10. Can J Psychiatry Revue Canadienne de Psychiatrie 2002, 47:196-197.
40. Invernissi R., Berettera C., Garattini S., Samanin R. d and l- isomers of fenfluramine differ markedly in their interaction with brain serotonin and catecholamines in the rat. Eur J Phararcmacol 1986, 120:9-15.
41. Koenigs M., Grafman J. The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex. Behav Brain Res 2009, 201:239-243.
42. Kohn Y., Freedman N., Lester H., Krausz Y., Chisin R., Lerer B., et al. 99mTc-HMPAO SPECT study of cerebral perfusion after treatment with medication and electroconvulsive therapy in major depression. JNuclear Med 2007, 48:1273-1278.
43. Kohn Y., Freedman N., Lester H., Krausz Y., Chisin R., Lerer B., et al. Cerebral perfusion after a 2-year remission in major depression. Int J Neuropsychopharmacol 2008, 11:837-843.
44. Kronmuller K.T., Schroder J., Kohler S., Gotz B., Victor D., Unger J., et al. Hippocampal volume in first episode and recurrent depression. Psychiatry Res 2009, 174:62-66.
45. Leuchter A.F., Cook I.A., Witte E.A., Morgan M., Abrams M. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry 2002, 159:122-129.
46. Leuchter A.F., Cook I.A., DeBrota D.J., Hunter A.M., Potter W.Z., McGrouther C.C., et al. Changes in brain function during administration of venlafaxine or placebo to normal subjects. Clin EEG Neurosci 2008, 39:175-181.
47. Loranger A., Sartorious N., Andreoli A. The World Health Organisation/alcohol, drug abuse and mental health administration international pilot study of personality disorders. Arch Gen Psychiatry 1994, 51:215-224.
48. Marmor M., Zrenner E. Standard for clinical electro-oculography. Arch Ophthalmol 1993, 601-604.
49. Mendlewicz J., Hubain P., Koumakis C. Further investigation of the dexamethasone suppression test in affective illness: relationship to clinical diagnosis and therapeutic response. Neuropsychobiol 1984, 12:23-26.
50. Moller H.J., Fountoulakis K.N. Problems in determining efficacy and effectiveness of antidepressants. Psychiatrike 2011, 22:298-306.
51. Nagafusa Y., Okamoto N., Sakamoto K., Yamashita F., Kawaguchi A., Higuchi T., et al. Assessment of cerebral blood flow findings using 99mTc-ECD single-photon emission computed tomography in patients diagnosed with major depressive disorder. JAffect Disord 2012, 140:296-299.
52. Nuller J., Ostroumova M. Resistance to inhibiting effect of dexamethasone in patients with endogenous depression. Acta Psychiatr Scand 1980, 61:169-177.
53. Ouattrone A., Tedeschi G., Aguglia U., Scopacasa F. Prolactin secretion in man: a useful tool to evaluate the activity of drugs on central 5-HT neurones. Studies with funfluramine. Br J Clin Pharmacol 1983, 16:471-475.
54. Pariante C.M. Risk factors for development of depression and psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressant and glucocorticoids. Ann N Y Acad Sci 2009, 1179:144-152.
55. Quattrone A., Schettini G., DiRenzo G. Effect of midbrain Raphe lesion or 5-7 dihydroxytryptamine treatment on the prolactin releasing action of quipazine and d-fenfluramine in rats. Brain Res 1979, 174:71-79.
56. Rogers M.A., Kasai K., Koji M., Fukuda R., Iwanami A., Nakagome K., et al. Executive and prefrontal dysfunction in unipolar depression: a review of neuropsychological and imaging evidence. Neurosci Res 2004, 50:1-11.
57. Rowland N., Carlton J. Neurobiology of an anorectic drug: fenfluramine. Prog Neurobiol 1986, 27:13-62.
58. Siever L., Murphy D. Plasma prolactin changes following fenfluramine in depressed patients compared to controls: an evaluation of central serotonergic responsivity in depression. Life Sci 1984, 34:1029-1039.
59. Stokes J.M., Pogge D.L., Powell-Lunder J., Ward A.W., Bilginer L., DeLuca V.A. The Rorschach Ego Impairment Index: prediction of treatment outcome in a child psychiatric population. JPers Assess 2003, 81:11-19.
60. The APA Task Force on Laboratory Tests in Psychiatry The dexamethasone suppression test: an overview of its current status in psychiatry. Am J Psychiatry 1987, 144:1253-1262.
61. Todd J., Green G., Harrison M., Ikuesan B.A., Self C., Baldacchino A., et al. Defining dual diagnosis of mental illness and substance misuse: some methodological issues. JPsychiatric Mental Health Nurs 2004, 11:48-54.
62. Williams C., Papakostopoulos D. Electro-oculographic abnormalities in amblyopia. Br J Ophthalmol 1995, 218-224.
63. Williams J.A. Structured interview guide for the Hamilton depression rating scale. Arch Gen Psychiatry 1988, 5:742-747.
64. Wing J., Babor T., Brugha T. SCAN: schedules for clinical assessment in neuropsychiatry. Arch Gen Psychiatry 1990, 47:589-593.
65. Zarifian E. Summary and conclusions. Clin Neuropharmacol 1993, 16:S51-S53.